COMPANY INFO
Dash Bio, officially known as Dash Bio, Inc., was founded in 2024 by Ander Tallett and Dave Johnson. It is a seed-stage biotechnology company based in Boston, Massachusetts, with 2-10 employees, operating an automated clinical bioanalysis platform that leverages AI and robotics to accelerate drug development by delivering high-quality assays with faster turnaround times than traditional methods. The company's website is www.dash.bio, and it operates in the biotechnology and pharmaceutical research industry.
Dash Bio, officially known as Dash Bio, Inc., is a seed-stage biotechnology company founded in 2024 by Ander Tallett and Dave Johnson. Based in Boston, Massachusetts, Dash Bio operates in the biotechnology and pharmaceutical research industry. The company employs an automated clinical bioanalysis platform powered by AI and robotics, accelerating drug development by delivering high-quality assays with faster turnaround times than conventional approaches. With a team of 8 professionals, Dash Bio aims to transform the delivery of bioanalytical services for clinical trials and pharmaceutical research.
Dash Bio funding history reflects a strong commitment to innovation in biotech, having raised a total of $6.5 million in seed capital. The company has completed a single funding round as of October 2024, representing a pivotal milestone for its initial launch, expansion of operations, and rapid product development. This seed round demonstrates a strategic approach to capital, targeting investors with deep expertise in early-stage biotech and AI-driven healthcare solutions. The overall Dash Bio funding strategy is focused on building scalable, tech-enabled clinical bioanalysis capabilities that appeal to both venture capital and industry partners.
The $6.5 million seed funding round was raised to support Dash Bio’s initial launch and drive product development. Proceeds are being used to expand operations, further develop its automated clinical bioanalysis platform, and accelerate customer acquisition in the pharmaceutical sector.
Freestyle Capital led the Dash Bio seed round, providing both funding and strategic advisory. As a top-tier venture capital firm with a focus on early-stage technology and healthcare startups, Freestyle Capital is instrumental in guiding Dash Bio’s integration of AI and automation, and in supporting its network growth within biotech and pharma.
Participating in the seed round, Swift Ventures brings deep expertise in biotech and life science investments. Swift Ventures supports Dash Bio’s go-to-market and commercialization strategies, leveraging its connections in the life sciences to foster growth and client relationships.
LifeX Ventures also participated in Dash Bio’s seed round, complementing the investor group with a focus on life science innovation. LifeX Ventures provides resources, mentorship, and industry access, aiding Dash Bio in refining its product and accelerating its fundraising and business development efforts.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Dash Bio funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.